

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
23 October 2003 (23.10.2003)

PCT

(10) International Publication Number  
**WO 03/086402 A1**

(51) International Patent Classification<sup>7</sup>: **A61K 31/496, C07D 215/56**

REDDY, Ningam, Srinivas [IN/IN]; 7-1-27, Ameerpet, Hyderabad, A.P., 500 016 (IN). KUMAR, rapolu, Rajesh [IN/IN]; 7-1-27, Ameerpet, Hyderabad, A.P., 500 016 (IN).

(21) International Application Number: **PCT/US03/10708**

(74) Agents: CORD, Janet, I. et al.; Ladas & Parry, 26 West 61st Street, New York, NY 10023 (US).

(22) International Filing Date: 7 April 2003 (07.04.2003)

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PI, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
259/MAS/2002 8 April 2002 (08.04.2002) IN  
285/MAS/2002 12 April 2002 (12.04.2002) IN

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(71) Applicant (*for all designated States except GD, US*): DR. REDDY'S LABORATORIES LIMITED [IN/IN]; 7-1-27, Ameerpet, Hyderabad, A.P. 500 016 (IN).

Published:

— with international search report

(71) Applicant (*for GD only*): CORD, Janet, I. [US/US]; 26 West 61st Street, New York, NY 10023 (US).

(72) Inventors; and


(75) Inventors/Applicants (*for US only*): REDDY, Manne, Satyanarayana [IN/IN]; 7-1-27, Ameerpet, Hyderabad, A.P., 500 016 (IN). RAJU, Chakilam, Naga [IN/IN]; 7-1-27, Ameerpet, Hyderabad, A.P., 500 016 (IN). RAJU, Vetukuri, Venkata, Naga, Kali, vara, Prasada [IN/IN]; 7-1-27, Ameerpet, Hyderabad, A.P., 500 016 (IN).

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: ANHYDROUS CRYSTALLINE FORMS I AND II OF 1-CYCLOPROPYL-6-FLUORO-8-METHOXY-7-(3-METHYL-1-PIPERAZINYL) 4-OXO-1, 4-DIHYDROQUINOLINE-3-CARBOXYLIC ACID (GATIFLOXACIN)



WO 03/086402 A1



(57) Abstract: The present invention relates to the novel anhydrous crystalline forms I and II of 1-cyclopropyl-6-fluoro-8-methoxy-7-(3-methyl-1-piperazinyl) 4-oxo-1, 4-dihydroquinoline-3-carboxylic acid (gatifloxacin) which can be depicted as Formula (I). The present invention also relates to methods of making the anhydrous Forms I and II of Gatifloxacin, use of the forms and methods for preparing them.


**ANHYDROUS CRYSTALLINE FORMS I AND II OF 1-CYCLOPROPYL-6-FLUORO-8-METHOXY-7-(3-METHYL-1-PIPERAZINYL) 4-OXO-1, 4-DIHYDROQUINOLINE-3-CARBOXYLIC ACID (GATIFLOXACIN)**

The present invention relates to novel anhydrous crystalline Forms of 1-

- 5 Cyclopropyl-6-fluoro-8-methoxy-7-(3-methyl-1-piperazinyl)-4-oxo 1,4-dihydro-  
quinoline 3-carboxylic acid. The present invention also relates to methods of making  
these anhydrous Forms of Gatifloxacin.

10 1-Cyclopropyl-6-fluoro-8-methoxy-7-(3-methyl-1-piperazinyl)-4-oxo 1, 4-dihydroquinoline-3-carboxylic acid is generically known as Gatifloxacin and is marketed under brand name "Tequin".

Gatifloxacin can be depicted as Formula (I).



Gatifloxacin and its pharmaceutically acceptable salts are useful as antibiotics.

15 Quinolone carboxylic acid derivatives constitute a class of extremely potent and orally active broad-spectrum antibacterial agents. Several structural activity relationship (SAR) and quantitative structure activity relationship (QSAR) studies have led to the discovery of an important class of quinolines called fluoroquinolones.

20 Gatifloxacin of Formula (I) belonging to the class of fluoroquinolones has potent antibacterial activity. Gatifloxacin also has higher selectivity against bacteria from mammalian cells which results in excellent selective toxicity.

Gatifloxacin is preferably administered orally or intravenously. The usual dose of Gatifloxacin is 400mg once daily.

- 2 -

Several references disclose the structure of Gatifloxacin and U.S. Patent 4,980,470, incorporated herein by reference, describes the synthesis of Gatifloxacin hemihydrate. Gatifloxacin hemihydrate is prepared by condensing 1-cyclopropyl-6, 7-difluoro-1, 4-dihydro-4-oxo-8-methoxy quinoline-3-carboxylic acid with 2-methyl 5 piperezine in DMSO, accompanied by chromatographic purification.

U.S. 5,880,283 discloses preparation of the Gatifloxacin sesquihydrate, which involves heating the mixture of 1-Cyclopropyl-6-fluoro-8-methoxy-7-(3-methyl-1-piperazinyl)-4-oxo-1, 4-dihydroquinoline-3-carboxylic acid with water, preferably 3-5 times the weight of reactant, at 80-85 °C and subsequent filtration and drying resulting in 10 the sesquihydrate of Gatifloxacin.

Japanese unexamined Patent Publication 63-198664, discloses 15 Gatifloxacin hydrochloride salts. The publications states that the hemihydrate and hydrochloride salt of Gatifloxacin are unstable due to the hygroscopic nature of the drug substance. Problems are encountered due to its poor disintegration and dissolution rate while formulating the tablets.

The present invention is directed to anhydrous crystalline forms of Gatifloxacin, which are non-hygroscopic, crystalline and non-solvated. Generally, the hygroscopic nature is due to the presence of impurities, but the present inventive Forms are non- hygroscopic, which infers the high purity of the compounds. The present 20 inventive Forms are produced in non- solvated form, i.e., the content of residual solvents are well within the limits as per ICH guidelines; hence they are well suited for pharmaceutical formulations.

Another aspect of the present invention is to provide processes for the preparation of the anhydrous crystalline Form I and II of Gatifloxacin, which are cost 25 effective, commercially viable and well suited for industrial scale up.

#### BRIEF DESCRIPTION OF THE ACCOMPANYING DRAWING

Fig. 1 is a diagram showing the results of thermogravimetric analysis of the anhydrous crystalline Form I of Gatifloxacin.

Fig. 2 is a diagram showing the results of X-ray diffraction of the 30 anhydrous crystalline Form I of Gatifloxacin.

Fig. 3 is a diagram showing the results of DSC of the anhydrous crystalline Form I of Gatifloxacin.

- 3 -

Fig. 4 is a diagram showing the IR spectrum of the anhydrous crystalline Form I of Gatifloxacin.

Fig. 5 is a diagram showing the results of X-ray diffraction of anhydrous crystalline Form II of Gatifloxacin.

5 Fig. 6 is a diagram showing the results of DSC of the anhydrous crystalline Form II of Gatifloxacin.

Fig. 7 is a diagram showing the IR spectrum of anhydrous crystalline Form II of Gatifloxacin.

10 The present invention provides anhydrous crystalline Forms I and II of Gatifloxacin of Formula (1) and processes for the preparation thereof.

The crystalline nature of anhydrous Form I and II of Gatifloxacin is characterized by their respective X-ray diffractograms, Differential Scanning colorimetry thermograms and IR spectra.

15 The anhydrous nature of the Forms I and II was characterized by their respective thermogravimetric analysis, and the anhydrous nature of the compounds was also confirmed by calculating the water content present in the compounds by Karl Fischer (KF) method.

20 The moisture content of the anhydrous Form I of Gatifloxacin ranges from 0.05% to 2.0% by KF and as per thermogravimetric analysis, which is less than the hemihydrate. This confirms the anhydrous nature of the compound. Preferably Form I of Gatifloxacin has a moisture content of 0.4% by KF method.

The present invention provides the thermogram of thermo gravimetric analysis of anhydrous Form I of Gatifloxacin substantially as depicted in Figure 1.

25 The report of thermogravimetric analysis shows a total weight loss of 0.6% at a temperature range of 0-250°C. The result indicates the anhydrous nature of the Form I of Gatifloxacin.

30 The X-ray powder diffraction pattern of anhydrous crystalline Form I was measured on a Bruker Axs, D8 Advance Powder X-ray Diffractometer with Cu K alpha-1 Radiation source. The samples was scanned between 3 and 45 degrees 2 theta. The anhydrous crystalline Form I of Gatifloxacin has X-ray powder diffraction pattern essentially as shown in the Table-1. The X-ray powder diffraction pattern is expressed in terms of the 2 theta (degrees), and percentage of intensity.

- 4 -

TABLE 1

2 theta (°)	Intensity (%)
7.763	100
19.722	100
13.615	89.3
25.927	71.9
12.854	71.7
28.65	40.9
20.491	35.2
14.112	29.3
10.196	26.8
23.593	15.1
23.765	14.9
16.333	12.2
27.558	10.9
14.932	9.8
21.456	9.7
30.496	8.4
17.013	7.2
30.872	6.7
31.477	5.6
24.44	3.7

The present invention of anhydrous crystalline Form I of Gatifloxacin is characterized by its X-ray powder diffraction substantially as depicted in Figure 2.

5 The Differential Scanning Calorimetry thermogram of crystalline Form I exhibits a significant endo peak at 188.35°C and is substantially as depicted in Figure 3.

The Infrared data for anhydrous crystalline Form I of Gatifloxacin, was measured by KBr-transmission method and is substantially as depicted in Fig. 4 and shows significant peaks about 3327.7 and 1721.0 cm<sup>-1</sup>.

10 Another embodiment of the present invention is to provide a process for the preparation of anhydrous crystalline Form I of Gatifloxacin. Anhydrous crystalline Form I of Gatifloxacin can be prepared by a process which comprises the azeotropic removal of water from a hydrated form of Gatifloxacin at reflux temperature using an aromatic or aliphatic hydrocarbon solvent or a ketone solvent. The process comprises:

15 i) refluxing azeotropically a hydrated form of Gatifloxacin in

- 5 -

water-immiscible aromatic or aliphatic hydrocarbon solvent or ketone solvent;

ii) cooling the reaction mixture of step (i) accompanied by stirring of the mixture until the solid mass crystallizes;

iii) isolating the solid obtained in step (ii) by conventional methods;

5 and

iv) drying the isolated solid of step (iii) at 30-70°;

v) dissolving the solid isolated in step iv) in a linear or branched chain substituted or unsubstituted alkanone solvent at reflux temperature;

vi) cooling to 0-5°C;

10 vii) filtering and washing with a linear or branched chain substituted or unsubstituted alkanone solvent; and

viii) drying at 30-90°C to obtain anhydrous crystalline Form I of Gatifloxacin.

Preferably the ratio of hydrated Gatifloxacin to solvent is 1:1 to 10 w/w,

15 preferably 1:5 w/v.

As used herein aliphatic hydrocarbon means linear, branched or cyclic hydrocarbon.

Preferably the aromatic or aliphatic hydrocarbon solvent is selected from benzene, toluene, xylene, or cyclohexane. Preferably the ketone is selected from methyl 20 ethyl ketone, methyl isobutyl ketone or methyl tertiary butyl ketone. The preferred solvent is toluene. In step (iii) the solid can be isolated by filtration, decanting, or centrifugation or a combination of these methods.

Preferably in step iv) the solid is dried at 50-60°C.

The ratio of solid to solvent in step v) is the range of 1-40 w/v:1-40 w/v.

25 Preferably the solvent used in steps v) and vii) is acetone. Preferably the solid in step viii) the solvent is dried at 40-70°C.

The anhydrous crystalline Form II of Gatifloxacin of this invention also has a moisture content from 0.05% to 2.0% by KF and as per thermogravimetric analysis, which is less than the hemihydrate. Preferably, the moisture content is 0.48% by KF.

30 Anhydrous crystalline polymorph Form II of Gatifloxacin has a moisture content of 0.48% by KF method, which confirms the anhydrous nature of the compound.

- 6 -

- The X-ray powder diffraction pattern of anhydrous crystalline polymorph Form II was measured on a Bruker Axs, D8 Advance Powder X-ray Diffractometer with Cu K alpha-1 Radiation source. The sample was scanned between 3 and 45 degrees 2 theta. The anhydrous crystalline polymorph Form II of Gatifloxacin has X-ray powder diffraction pattern essentially as shown in the Table-2. The X-ray powder diffraction pattern is expressed in terms of the 2 theta (degrees), and percentage of intensity.
- 5      The X-ray powder diffraction pattern of anhydrous crystalline polymorph Form II was measured on a Bruker Axs, D8 Advance Powder X-ray Diffractometer with Cu K alpha-1 Radiation source. The sample was scanned between 3 and 45 degrees 2 theta. The anhydrous crystalline polymorph Form II of Gatifloxacin has X-ray powder diffraction pattern essentially as shown in the Table-2. The X-ray powder diffraction pattern is expressed in terms of the 2 theta (degrees), and percentage of intensity.

**TABLE 2**

2 theta (°)	Intensity (%)
5.931	100
14.116	68.5
22.509	33.7
21.073	31.3
15.833	20.7
27.571	15.9
27.807	15.6
11.248	13.0
12.426	10.2
23.249	9.2
11.906	8.6
24.287	8.0
29.389	6.2
21.507	4.7
24.943	4.3
17.991	3.7
19.646	3.2
18.667	3.0
39.841	2.3
26.918	2.3
28.504	2.2
16.276	2.2

- The present invention of anhydrous crystalline polymorph Form-II of  
10      Gatifloxacin is characterized by its X-ray powder diffraction pattern substantially as depicted in Figure 5.

The Differential Scanning Calorimetry thermogram of crystalline Polymorph Form II exhibits a significant endo peak at 187.71 °C and is substantially as

depicted in Figure 6.

Infrared data for anhydrous crystalline polymorph Form-II of Gatifloxacin, was measured by KBr-transmission method and is substantially as depicted in Fig. 7 with identified significant peaks at about 1620.9 and 1728.3 cm<sup>1</sup>.

5 Another embodiment of the present invention is to provide a process for the preparation of novel anhydrous crystalline Form II of Gatifloxacin. Anhydrous crystalline polymorph Form II of Gatifloxacin can be prepared by a process which comprises the azeotropic removal of water from hydrated form of Gatifloxacin at reflux temperature using an aliphatic hydrocarbon solvent. The process comprises:

- 10 i) refluxing azeotropically a hydrated form of Gatifloxacin in a water-immiscible aliphatic hydrocarbon solvent;
- ii) cooling the reaction mixture of step (i) accompanied by stirring of the mixture until the solid mass crystallizes;
- iii) isolating the solid obtained in step (ii) by conventional methods;
- 15 and
- iv) drying the isolated solid of step (iii) with or without vacuum at 30-70°C to obtain anhydrous crystalline polymorph Form-II of Gatifloxacin.

Preferably the ratio of hydrated Gatifloxacin to solvent is 1:1 to 10 w/w, preferably 1:5 w/v.

20 As used herein aliphatic hydrocarbon means linear, branched or cyclic hydrocarbon. Preferably, the aliphatic hydrocarbon solvent is cyclohexane.

Preferably, the solid is dried at 40-50°C.

The anhydrous crystalline Forms I and II Gatifloxacin can be prepared from any hydrated Form of Gatifloxacin.

25 These processes are commercially viable and well suited for industrial scale up.

In step (iii) the solid can be isolated by filtration, decanting or centrifugation or a combination of these methods.

Preferred salts of Form I or II of Gatifloxacin are hydrochloride salts.

30 The compounds of this invention have antibacterial activity and are useful as antibiotics.

The present invention also envisages pharmaceutical compositions of the

- 8 -

anhydrous crystalline Form I and II of 1-Cyclopropyl- 6-fluoro-8-methoxy-7-(3-methyl-1-piperazinyl)-4-oxo-1, 4-dihydro-quinoline-3-carboxylic acid. The compositions may include a physiological acceptable carrier, diluent, excipient, additive, filler, lubricant, binder, stabilizer, solvent or solvate or a mixture thereof.

5       The pharmaceutical composition may be in a form normally employed, such as tablets, capsules, lozenges, powders, syrups, solutions, suspensions, ointments, dragees and the like, may contain flavourants, sweetners, etc. in suitable solid or liquid carriers or diluents, or in suitable sterile media to form injectable solutions or suspensions. Such compositions typically contain from 1 to 25%, preferably 1 to 15% by  
10 weight of active ingredient, the remainder of the composition being one or more of a pharmaceutically acceptable carrier, diluent, excipient, additive, filler, lubricant, binder, stabilizer, solvent or solvate.

The anhydrous crystalline Forms of 1-Cyclopropyl-6-fluoro-8-methoxy-7-(3-methyl-1-piperazinyl)-4-oxo-1, 4-dihydro-quinoline-3-carboxylic acid can be  
15 administered to mammals, including man, via either oral, nasal, pulmonary, transdermal or parenteral, rectal, depot, subcutaneous, intravenous, intraurethral; intramuscular, intranasal, ophthalmic solution or an ointment. Administration by the oral route is preferred, being more convenient and avoiding the possible pain and irritation of injection. However, in circumstances where the patient cannot swallow the medication,  
20 or absorption following oral administration is impaired, as by disease or other abnormality, it is essential that the drug be administered parenterally. By either route, the dosage is in the range or about 0.01 to about 100 mg/kg body weight of the subject per day or preferably about 0.01 to about 100 mg/kg body weight of the subject per day or preferably about 0.01 to about 30 mg/kg body weight per day administered singly or as a  
25 divided dose. However, the optimum dosage for the individual subject being treated will be determined by the person responsible for treatment, generally smaller doses being administered initially and thereafter increments made to determine the most suitable dosage.

Suitable pharmaceutically acceptable carriers include solid fillers or  
30 diluents and sterile aqueous or organic solutions. The active ingredient will be present in such pharmaceutical compositions in the amounts sufficient to provide the desired dosage in the range as described above. Thus, for oral administration, the compound can be

- 9 -

- combined with a suitable solid or liquid carrier or diluent to form capsules, tablets, powders, syrups, solutions, suspensions and the like. The pharmaceutical compositions, may, if desired, contain additional components such a flavourants, sweeteners, excipients and the like. For parenteral administration, the compound can be combined with sterile  
5 aqueous or organic media to form injectable solutions or suspensions. For example, solutions in sesame or peanut oil, aqueous solutions of water-soluble pharmaceutically-acceptable acid addition salts or salts with base of the compounds. Aqueous solutions with the active ingredient dissolved in polyhydroxylated castor oil may also be used for injectable solutions. The injectable solutions prepared in this manner can then be  
10 administered intravenously, intraperitoneally, subcutaneously, or intramuscularly, with intramuscular administration being preferred in humans.

For nasal administration, the preparation may contain the compound of the present invention dissolved or suspended in a liquid carrier, in particular an aqueous carrier, for aerosol application. The carrier may contain additives such as solubilizing  
15 agents, such as propylene glycol, surfactants, absorption enhancers such as lecithin (phosphatidylcholine) or cyclodextrin or preservatives such as parabenes.

Tablets, dragees or capsules having talc and/or a carbohydrate carried binder or the like are particularly suitable for any oral application. Preferably, carriers for tablets, dragees or capsules include lactose, corn starch and/or potato starch. A syrup or  
20 elixir can be used in cases where a sweetened vehicle can be employed. An effective amount means that amount of a drug or pharmaceutical agent that will elicit the biological or medical response of a tissue, system, human or animal sought.

The present invention will be explained in more detail by the following non-limiting examples.

25 Reference Example

1-cyclo-6, 7-difluoro-1, 4-dihydro-4-oxo-8-methoxy quinolone-3-carboxylic acid (100 grams 0.339 moles) and 2-methyl piperazine (100 grams 1.0 mole) was added to acetonitrile (500 ml) and the reaction mixture was slowly heated to the reflux temperature and stirred until the reaction was substantially complete. Then the  
30 solvent was distilled off completely and water (300 ml) was added to the residual mass. The reaction mass was cooled to the temperature of 40-50°C. The pH was adjusted towards acidic with acetic acid (250 ml). The mass was filtered off and then pH of the

- 10 -

filtrate was further adjusted to 6.0-8.0 with ammonia. The reaction mixture was cooled to a temperature of 10-15°C and stirred for 30-45 minutes. Thus, the obtained solid was successively recrystallized to afford Gatifloxacin; which had a moisture content ranging from 2.5 to 50.0%.

5

#### EXAMPLE 1

##### Preparation Of Anhydrous Crystalline Form I Of Gatifloxacin

Gatifloxacin hydrate 53 grams (obtained as per reference example) was suspended in toluene (250 ml) and heated to reflux to the temperature of 100-110°C. Water was azeotropically removed, accompanied by cooling of the reaction mixture to 10-10 15°C under stirring for 30-60 minutes to crystallize the solid mass. The crystallized solid mass was filtered, washed with toluene (50 ml) and dried at 50-60°C to constant weight. The obtained product is dissolved in acetone (20 times to solid quantity) at reflux 50-60°C and distill off 15 times of solvent to the initial volume (solid solvent ratio is 1:5 prior to isolation) and reaction mass is cooled to 0-5° and filtered, washed with Acetone (0.5-1.0 15 times to the input quantity). Finally product is dried at 50-60°C until constant weight is obtained.

(Weight: 38 grams, 40%, M.C. by KF is 0.40% and Purity: 99.83%).

#### EXAMPLE 2

##### Preparation Of Anhydrous Crystalline Polymorph Form II Of Gatifloxacin

Gatifloxacin hydrate (10 grams, 0.026 moles, prepared as per reference 20 example) was suspended in cyclohexane (50 ml) and heated to reflux to the temperature of 70-80°C. Water was azeotropically removed, accompanied by cooling of the reaction mixture to 0-10°C under stirring for 30-60 minutes to crystallize the solid mass. The crystallized solid mass was filtered, washed with cyclohexane (10 ml) and dried under 25 reduced pressure at a temperature of 40-50°C to constant weight.

(Weight: 9 grams, 90%, M.C. by KF is 0.48% and Purity: 99.58%).

#### Detailed Description Of The Accompanying Drawings

Fig. 1 is characteristic thermogram of thermal gravimetric analysis of 30 anhydrous crystalline form I of Gatifloxacin, shows a total weight loss of 0.60% (w/w) at a temperature range of 0-250°C indicates the anhydrous nature of the inventive substance of crystalline Form I of Gatifloxacin.

Vertical axis: weight of the compound (in mg); Horizontal axis:

- 11 -

Temperature (in °C). Vertical axis: Intensity (CPS); Horizontal axis: 2 Theta (degrees).

Scan speed: Time/step: 0.40 secs.

Sampling time: Scan Time: 14:0.40 min

Scan Mode: Continuous

5 Reflection: Geometry is reflection (nor transmission)

Scan Type: Locked coupled.

Fig: 2 is characteristic X-ray powder diffraction pattern of the novel anhydrous crystalline Form I of Gatifloxacin.

Vertical axis: Intensity (CPS); Horizontal axis: 2 Theta (degrees).

10 The significant 2 theta values (in degrees) obtained are 7.763, 10.196,

12.854, 13.615, 14.1112, 14.932, 16.333, 17.013, 19.722, 20.491, 21.456, 23.593, 23.765,

24.44, 25.927, 27.558, 28.65, 30.496, 30.872, and 31.477.

15 Fig: 3 is characteristic Differential Scanning Calorimetric thermogram of anhydrous crystalline Form I of Gatifloxacin. The Differential Scanning Calorimetric thermogram exhibits a significant endo peak at 188.35 °C.

Vertical axis: Temperature (in °C); Horizontal axis: Signal (in mV), Heating rate 5°/minute.

Fig: 4 is characteristic Infra Red spectrum of anhydrous crystalline Form I of Gatifloxacin with identified significant peaks at about 3327.7 and 1721.0 cm<sup>-1</sup>.

20 Vertical axis: Wave length (in Cm<sup>-1</sup>); Horizontal axis: Transmission (in %) KBr.

Fig: 5 is characteristic X-ray powder diffraction pattern of the anhydrous crystalline polymorph Form-II of Gatifloxacin.

Vertical axis: Intensity (CPS); Horizontal axis: 2 Theta (degrees).

25 Scan speed: Time/step: 0.40 secs.

Sampling time: Scan Time: 14:0.40 min

Scan Mode: Continuous

Reflection: Geometry is reflection (nor transmission)

Scan Type: Locked coupled.

30 The significant 2 theta values (in degrees) obtained are 5.931, 11.248,

11.906, 12.426, 14.116, 15.833, 16.276, 17.991, 18.667, 19.646, 21.073, 21.507, 22.509,

23.249, 24.287, 24.943, 26.918, 27.571, 27.807, 28.504, 29.389, and 39.841 degrees two

- 12 -

theta.

Fig. 6 is characteristic Differential Scanning Calorimetric thermogram of novel anhydrous crystalline polymorph Form II of Gatifloxacin. The Differential Scanning Calorimetric thermogram exhibits a significant endo peak at 187.71°C.

5 Vertical axis: Temperature (in °C); Horizontal axis: Signal (in mV), in Heating rate 5°/minute.

Fig. 7 is characteristic Infra Red spectrum of anhydrous crystalline polymorph Form II of Gatifloxacin with identified significant peaks at about 1620.9 and 1728.3 cm<sup>-1</sup>.

10 Vertical axis: Wave length (in Cm<sup>-1</sup>); Horizontal axis: Transmission (in %) KBr.

- 13 -

### CLAIMS

1. An anhydrous crystalline Form I of 1-Cyclopropyl-6-fluoro-8-methoxy-7-(3-methyl-1-piperazinyl)-4-oxo-1, 4-dihydroquinoline-3-carboxylic acid (Gatifloxacin).
2. The anhydrous crystalline Form I of Gatifloxacin according to claim 1,  
5 having a X-ray powder diffraction pattern with peaks at 7.763, 10.196, 12.854, 13.615, 14.112, 14.932, 16.333, 17.013, 19.722, 20.491, 21.456, 23.593, 23.765, 24.44, 25.927, 27.558, 28.65, 30.496, 30.872 and 31.477 two theta (degrees).
3. The anhydrous crystalline Form I of Gatifloxacin of claim 2, having an X-ray powder diffraction pattern substantially as depicted in Figure (2).
- 10 4. The anhydrous crystalline Form I of Gatifloxacin of claim 1, having a differential scanning colorimetry thermogram which exhibits a characteristic endo peak at 188.35°C.
5. The anhydrous crystalline Form I of Gatifloxacin of claim 4, having a differential scanning colorimetry thermogram substantially as depicted in Figure (3).
- 15 6. The anhydrous crystalline Form I of Gatifloxacin of claim 1, having identified characteristic peaks at about 3327.7 and 1721.0 cm<sup>1</sup> in the Infra red Spectrum.
7. The anhydrous crystalline Form I of Gatifloxacin of claim 1, having an Infra red Spectrum substantially as depicted in Figure (4).
- 20 8. A process for preparing anhydrous crystalline Form I of 1-Cyclopropyl-6-fluoro-8-methoxy-7-(3-methyl-1-piperazinyl)-4-oxo-1, 4-dihydroquinoline-3-carboxylic acid (Gatifloxacin), which comprises the steps of:
  - i) refluxing azeotropically a hydrated form of Gatifloxacin in a water-immiscible aromatic or aliphatic hydrocarbon solvent or a ketone solvent;
  - 25 ii) cooling the reaction mixture of step i) accompanied by stirring of the mixture until the solid mass crystallizes;
  - iii) isolating the solid obtained in step ii) by conventional methods;
  - iv) drying the solid obtained in of step iii) at 30-70°C;
  - v) dissolving the solid isolated in step iv) in a linear or branched chain substituted or unsubstituted alkanone solvent at reflux temperature;
  - 30 vi) cooling to 0-5°C;
  - vii) filtering and washing with a linear or branched chain substituted or unsubstituted alkanone solvent; and

- 14 -

viii) drying at 30-90°C to obtain anhydrous crystalline Form I of

Gatifloxacin.

9. The process according to claim 8, wherein the aromatic or hydrocarbon solvent is selected from benzene, toluene, xylene or cyclohexane.

5 10. The process according to claim 8, wherein the ketone solvent is selected from methyl ethyl ketone, methyl isobutyl ketone or methyl tertiary butyl ketone.

11. The process according to claim 8, wherein the aromatic hydrocarbon solvent is toluene.

12. An anhydrous crystalline polymorph Form II of 1-Cyclopropyl-6-fluoro-8-methoxy-7-(3-methyl-1-piperazinyl)-4-oxo-1, 4-dihydroquinoline-3-carboxylic acid (Gatifloxacin).

13. The anhydrous crystalline polymorph Form II of Gatifloxacin according to claim 12, having an X-ray powder diffraction pattern with peaks at 5.931, 11.248, 11.906, 12.426, 14.116, 15.833, 16.276, 17.991, 18.667, 19.646, 21.073, 21.507, 22.509, 23.249, 15 24.287, 24.943, 26.918, 27.571, 27.807, 28.504, 29.389, and 39.841 degrees two theta.

14. The anhydrous crystalline polymorph Form II of Gatifloxacin of claim 12, having X-ray powder diffraction pattern substantially as depicted in Figure 5.

15. The anhydrous crystalline polymorph Form II of Gatifloxacin of claim 12, having a differential scanning colorimetry thermogram which exhibits a characteristic 20 endo peak at 187.71 °C.

16. The anhydrous crystalline polymorph Form II of Gatifloxacin of claim 12, having differential scanning colorimetry thermogram substantially as depicted in Figure 6.

17. The anhydrous crystalline polymorph Form II of Gatifloxacin of claim 12, having identified characteristic peaks at about 1620.9 and 1728.3 cm<sup>1</sup> in the Infra red

25 Spectrum.

18. The anhydrous crystalline polymorph Form II of Gatifloxacin of claim 12, having an Infrared Spectrum substantially as depicted in Figure 7.

19. A process for preparing anhydrous crystalline polymorph Form II of 1-Cyclopropyl-6-fluoro-8-methoxy-7-(3-methyl-1-piperazinyl)-4-oxo-1, 4-dihydroquinoline-3-carboxylic acid (Gatifloxacin), which comprises the steps of:

i. refluxing azeotropically a hydrated form of Gatifloxacin in a water-immiscible aliphatic hydrocarbon solvent;

- 15 -


ii. cooling the reaction mixture of step (i) accompanied by stirring of the mixture until the solid mass crystallizes;

iii. isolating the solid obtained in step (ii) by conventional methods; and

5 iv. drying the isolated solid of step (iii) with or without vacuum at a temperature of 30-70°C, to obtain anhydrous crystalline polymorph Form II of Gatifloxacin.


20. A process according to step i) of claim 19, wherein the aliphatic hydrocarbon solvent is cyclohexane.

1/7

**FIG. 1**

27

FIG. 2



377




**FIG. 3**

FIG. 4




5/7

FIG. 5




6/7

FIG. 6



7/7

FIG. 7



## INTERNATIONAL SEARCH REPORT

International Application No  
PCT/US 03/10708

A. CLASSIFICATION OF SUBJECT MATTER  
IPC 7 A61K31/496 C07D215/56

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)  
IPC 7 A61K C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the International search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, CHEM ABS Data

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US 4 980 470 A (KYORIN PHARM CO LTD (JP)) 25 December 1990 (1990-12-25) cited in the application example 14	1-20
A	EP 0 805 156 A (KYORIN PHARM CO LTD (JP)) 5 November 1997 (1997-11-05) cited in the application claim 1	1-20
A	US 4 997 943 A (SANKYO CO LTD (JP)) 5 March 1991 (1991-03-05) cited in the application example 22	1-20



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

## \* Special categories of cited documents :

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

\*T\* later document published after the International filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

\*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

\*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

\*&\* document member of the same patent family

Date of the actual completion of the international search

28 July 2003

Date of mailing of the International search report

05/08/2003

## Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

## Authorized officer

Cortés, J

**INTERNATIONAL SEARCH REPORT**

Information on patent family members

International Application No
PCT/US 03/10708

Patent document cited in search report		Publication date		Patent family member(s)		Publication date
US 4980470	A	25-12-1990	JP	8009597 B		31-01-1996
			JP	62252772 A		04-11-1987
			AU	610491 B2		23-05-1991
			AU	6769087 A		23-07-1987
			CA	1340316 C		12-01-1999
			CN	87100580 A , B		19-08-1987
			CY	2022 A		20-02-1998
			DE	3789878 D1		30-06-1994
			DE	3789878 T2		05-01-1995
			EP	0230295 A2		29-07-1987
			HK	79797 A		20-06-1997
			HU	43583 A2		30-11-1987
			JP	2631640 B2		16-07-1997
			JP	7304706 A		21-11-1995
			JP	2640441 B2		13-08-1997
			JP	7304742 A		21-11-1995
			JP	2598737 B2		09-04-1997
			JP	6092937 A		05-04-1994
			JP	6080640 A		22-03-1994
			KR	9407308 B1		12-08-1994
			US	5043450 A		27-08-1991
EP 0805156	A	05-11-1997	JP	8176143 A		09-07-1996
			AT	216381 T		15-05-2002
			AU	694946 B2		06-08-1998
			AU	3994695 A		10-07-1996
			DE	69526453 D1		23-05-2002
			DE	69526453 T2		12-12-2002
			DK	805156 T3		06-05-2002
			EP	0805156 A1		05-11-1997
			US	5880283 A		09-03-1999
			CA	2208704 A1		27-06-1996
			CN	1171108 A		21-01-1998
			ES	2173982 T3		01-11-2002
			HU	77945 A2		28-12-1998
			WO	9619472 A1		27-06-1996
			PT	805156 T		30-09-2002
			TW	393479 B		11-06-2000
US 4997943	A	05-03-1991	AU	618235 B2		19-12-1991
			AU	7078587 A		08-10-1987
			CA	1339537 C		11-11-1997
			CN	87103693 A , B		30-03-1988
			DK	164287 A		01-10-1987
			EP	0241206 A2		14-10-1987
			FI	871419 A		01-10-1987
			FI	953246 A		30-06-1995
			FI	962676 A		28-06-1996
			JP	1878384 C		07-10-1994
			JP	5081590 B		15-11-1993
			JP	63198664 A		17-08-1988
			KR	9601918 B1		06-02-1996
			KR	9514221 B1		23-11-1995
			NO	871333 A		01-10-1987

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:



**BLACK BORDERS**

**IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**

**FADED TEXT OR DRAWING**

**BLURRED OR ILLEGIBLE TEXT OR DRAWING**

**SKEWED/SLANTED IMAGES**

**COLOR OR BLACK AND WHITE PHOTOGRAPHS**

**GRAY SCALE DOCUMENTS**

**LINES OR MARKS ON ORIGINAL DOCUMENT**

**REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**

**OTHER:** \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**